



# Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis

**BACKGROUND:** Myeloid cells are central to atherosclerotic lesion development and vulnerable plaque formation. Impaired ability of arterial phagocytes to uptake apoptotic cells (efferocytosis) promotes lesion growth and establishment of a necrotic core. The transcription factor interferon regulatory factor (IRF)-5 is an important modulator of myeloid function and programming. We sought to investigate whether IRF5 affects the formation and phenotype of atherosclerotic lesions.

**METHODS:** We investigated the role of IRF5 in atherosclerosis in 2 complementary models. First, atherosclerotic lesion development in hyperlipidemic apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice and ApoE<sup>-/-</sup> mice with a genetic deletion of IRF5 (ApoE<sup>-/-</sup>Irf5<sup>-/-</sup>) was compared and then lesion development was assessed in a model of shear stress-modulated vulnerable plaque formation.

**RESULTS:** Both lesion and necrotic core size were significantly reduced in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice compared with IRF5-competent ApoE<sup>-/-</sup> mice. Necrotic core size was also reduced in the model of shear stress-modulated vulnerable plaque formation. A significant loss of CD11c<sup>+</sup> macrophages was evident in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice in the aorta, draining lymph nodes, and bone marrow cell cultures, indicating that IRF5 maintains CD11c<sup>+</sup> macrophages in atherosclerosis. Moreover, we revealed that the CD11c gene is a direct target of IRF5 in macrophages. In the absence of IRF5, CD11c<sup>-</sup> macrophages displayed a significant increase in expression of the efferocytosis-regulating integrin-β3 and its ligand milk fat globule-epidermal growth factor 8 protein and enhanced efferocytosis in vitro and in situ.

**CONCLUSIONS:** IRF5 is detrimental in atherosclerosis by promoting the maintenance of proinflammatory CD11c<sup>+</sup> macrophages within lesions and controlling the expansion of the necrotic core by impairing efferocytosis.

Anusha N. Seneviratne, PhD\*  
 Andreas Edsfeldt, MD, PhD\*  
 Jennifer E. Cole, PhD†  
 Christina Kassiteridi, PhD†  
 Maarten Swart, MSc  
 Inhye Park, MRes, BSc  
 Patricia Green, Dip Hon  
 Tariq Khoiratty, BSc  
 David Saliba, PhD  
 Michael E. Goddard, BSc  
 Stephen N. Sansom, PhD  
 Isabel Goncalves, MD, PhD  
 Rob Krams, PhD  
 Irina A. Udalova, PhD  
 Claudia Monaco, MD, PhD

\*Drs Seneviratne and Edsfeldt contributed equally as first authors.  
 †Drs Cole and Kassiteridi contributed equally as second authors.

**Correspondence to:** Claudia Monaco, MD, PhD, Kennedy Institute of Rheumatology, Roosevelt Drive, Headington, Oxford, United Kingdom. E-mail claudia.monaco@kennedy.ox.ac.uk

Sources of Funding, see page 1152

**Key Words:** atherosclerosis ■ CD11c ■ efferocytosis ■ IRF5 ■ macrophages

© 2017 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

## Clinical Perspective

### What Is New?

- Using murine models of atherosclerosis, we provide evidence for a pathogenic role for the transcription factor interferon regulatory factor (IRF5) in atherosclerosis.
- Atherosclerosis-prone apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice deficient in IRF5 (ApoE<sup>-/-</sup>Irf5<sup>-/-</sup>) exhibit reduced atherosclerotic lesion and necrotic core formation compared with IRF5-competent ApoE<sup>-/-</sup> mice.
- We reveal that development of the lesion necrotic core is controlled by IRF5 through impairment of macrophage efferocytosis (dead cell removal) through the molecules milk fat globule-epidermal growth factor 8 protein and integrin  $\beta$ -3.
- We further demonstrate that the CD11c gene is a direct target of IRF5 in macrophages and that IRF5 is important in maintaining CD11c<sup>+</sup> macrophages in atherosclerotic lesions.

### What Are the Clinical Implications?

- Larger necrotic cores are associated with an unstable atherosclerotic plaque phenotype, which is more likely to rupture and manifest as acute clinical complications.
- IRF5 contributes to a vulnerable plaque phenotype by maintaining proinflammatory CD11c<sup>+</sup> macrophages in the plaque and impairing efferocytosis, causing larger necrotic cores.
- Currently, no therapies are available that specifically target plaque inflammation and efferocytosis and modulate plaque stability.
- IRF5 is a potential therapeutic target because IRF5 inhibition could reduce plaque inflammation and necrotic core size and therefore promote a stable plaque phenotype with lower risk of acute clinical complications.

**A**therosclerosis, through causing heart attacks and strokes, is responsible for nearly half of deaths worldwide.<sup>1</sup> The presence of mononuclear phagocytes within the innermost intimal layer of the arterial wall is the hallmark of atherosclerosis and is necessary for its development.<sup>2,3</sup> The variety of macrophage subsets described in atherosclerosis is testament to the plasticity of this cell, with cell programming driven by lipids, inflammation, and hemorrhage.<sup>4</sup> Macrophages are crucial for programmed apoptotic cell removal or efferocytosis during atherogenesis and inflammation.<sup>5</sup> Impaired efferocytosis, resulting from either the persistent expression of don't eat me signals such as CD47 on apoptotic cells<sup>6</sup> or the cleavage of efferocytic receptors,<sup>7</sup> leads to larger necrotic cores that are a feature of high-risk lesions. The mechanisms linking macrophage

programming with efferocytosis function are ill defined.

The transcription factor interferon regulatory factor (IRF)-5 is a master regulator of inflammatory macrophage programming.<sup>8,9</sup> Granulocyte macrophage colony-stimulating factor (GM-CSF) and interferon- $\gamma$  treatment increases IRF5 expression.<sup>8,9</sup> Toll like receptor activation of myeloid differentiation primary response gene 88 signaling leads to phosphorylation of IRF5 and its nuclear translocation.<sup>9</sup> Genetic deletion of IRF5 protects from murine inflammatory arthritis and insulin resistance in diet-induced obesity,<sup>10,11</sup> while its inhibition with nanoparticles decreases myocardial infarct size.<sup>12</sup>

Despite the widespread prevalence of atherosclerosis in the population, acute complications arise in vulnerable patients with unfavorable plaque morphologies, such as thin-cap fibroatheroma (TCFA). TCFA is characterized by a large necrotic core surrounded by a thin protective fibrous cap containing fewer smooth muscle cells.<sup>13</sup> We have previously shown that hemodynamic factors may be relevant to TCFA formation. Low shear stress (LSS) occurs in the inner curvatures of vessels (eg, in the aortic arch and coronary arteries) and upstream of stenosis. In murine models, exposure to LSS leads to the development of plaque morphologies that resemble human TCFA.<sup>14</sup> We have also previously shown that IRF5 expression is enhanced in arterial regions exposed to LSS.<sup>15</sup>

In the present study, we evaluated the effect of IRF5 deficiency on the development of atherosclerosis in 2 complementary murine models. Loss of IRF5 expression reduced aortic lesion and necrotic core size in atherosclerosis-prone apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice. Furthermore, arterial segments exposed to LSS developed smaller necrotic cores and displayed a higher content of smooth muscle cells in IRF5-deficient ApoE<sup>-/-</sup> mice. Loss of IRF5 significantly reduced CD11c expression and infiltration of CD11c<sup>+</sup> macrophages in the aorta and draining lymph nodes while promoting the ability of macrophages to perform efferocytosis by integrin  $\beta$ -3 (Itgb3) and milk fat globule-epidermal growth factor 8 protein (Mfge8). Our data indicate that IRF5 is a key regulator of efferocytosis and necrotic core formation in atherosclerosis.

## METHODS

### Mice

ApoE<sup>-/-</sup> mice on a C57BL/6 background were purchased from Charles River Laboratories and bred in-house. Irf5<sup>-/-</sup> mice on a C57BL/6 background (from Professor Irina Udalova) were bred with ApoE<sup>-/-</sup> mice to generate ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice and their littermates (referred to as ApoE<sup>-/-</sup> mice thereafter). Experimental animals were negative for the Dock2 mutation.<sup>16</sup> Animals were housed under specific pathogen-free conditions and studied according to UK Home Office regulations and institutional guidelines. Only male mice were used in this study.

## Murine Lesion Analysis and Staining

Aortic root and cast-induced carotid lesion sections were stained and quantified as described in the [online-only Data Supplement Methods](#). In situ efferocytosis was assessed in cast-induced carotid lesion sections stained for apoptosis (TUNEL), DNA (7AAD), and CD68 as described in [online-only Data Supplement Methods](#).

## Analysis of Aortas and Para-Aortic Lymph Nodes (PALNs)

Aortas and PALNs were harvested from 20-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice. Single-cell suspensions were stained with antibodies and analyzed by flow cytometry or RNA was extracted and gene expression was analyzed using reverse transcription polymerase chain reaction, performed using Taqman assays as described in the [online-only Data Supplement Methods](#).

## Bone Marrow Macrophage Culture and Functional Assays

Bone marrow macrophages were isolated from ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice and cultured with GM-CSF as described in [online-only Data Supplement Methods](#). Functional assays including apoptosis, foam cell, phagocytosis, and efferocytosis assays (including siRNA knockdown of Itgb3 and Mfge8) were then performed as described in the [online-only Data Supplement Methods](#).

## Chromatin Immunoprecipitation and Next-Generation Sequencing

The IRF5 chromatin immunoprecipitation sequencing analysis was performed as previously described (accession number: E-MTAB-2661)<sup>17</sup> to determine the role of IRF5 as a regulator of CD11c expression.

## Human Carotid Plaques

Human carotid plaques from the Carotid Plaque Imaging Project biobank were analyzed as described in the [online-only Data Supplement Methods](#). Informed consent was given by each patient, and the study was approved by the local ethical committee.

## Statistical Methods

Data were analyzed with GraphPad Prism (v6.0c) or the R WRS2 package. Normally distributed variables are expressed as mean±SEM, and non-normally distributed variables are expressed as median and interquartile range (IQR). For aortic root lesion area and immunohistochemical staining in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice, the significance of changes in the main effects (time, genotype, and their interaction) was assessed using a robust 2-way ANOVA. For each parameter of interest in these data, Bonferroni-corrected nonparametric (Mann-Whitney *U*) planned tests were performed to assess the effect of genotype at each time point. Data from cast-induced carotid lesions were similarly analyzed using a mixed robust 2-way ANOVA to account for the paired observations

of low and oscillatory stress. We used Bonferroni-corrected nonparametric (Mann-Whitney *U*) planned tests to assess the effect of (1) genotype within stress type (unpaired test), and (ii) stress type within genotype (paired test). The use of nonparametric and robust ANOVA methods was motivated by observations of non-normality and unequal group variances. The significant findings from the planned tests are reported in the figures, and results of the ANOVA analyses are summarized in [Tables I–V in the online-only Data Supplement](#). In the remainder of the article, data were analyzed with Student's *t* test, Mann-Whitney *U* test, 1-way ANOVA, and Spearman's or Pearson's correlation coefficient as appropriate. The Benjamini-Hochberg method was used to adjust the *P* values for multiple testing as necessary.

## RESULTS

### IRF5 Is Expressed in Atherosclerotic Lesions by Myeloid Cells

Expression of IRF5 was examined in aortic root lesions of ApoE<sup>-/-</sup> mice 12, 20, and 27 weeks of age. Maximal IRF5 expression (6.3±2.5% of lesion area) was observed at 20 weeks of age ([Figure 1A in the online-only Data Supplement](#)). Using confocal microscopy, IRF5 staining in the atherosclerotic lesion was observed in CD68- and CD11c-expressing cells. Nuclear translocation could also be observed ([Figure 1B and C in the online-only Data Supplement](#)). Conversely, expression of  $\alpha$ -smooth muscle actin in the intima of the lesion did not colocalize with IRF5 staining ([Figure 1D in the online-only Data Supplement](#)).

### IRF5 Deficiency Reduces Atherosclerotic Lesion and Necrotic Core Size

ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice were fed a chow diet and euthanized at 15, 20, or 27 weeks of age. No difference in serum cholesterol levels was observed between ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice at any time point examined ([Table VI in the online-only Data Supplement](#)). ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice were heavier than ApoE<sup>-/-</sup> mice at 15 weeks of age, in keeping with published studies ([Table VI in the online-only Data Supplement](#)).<sup>10</sup>

Lesion size was assessed in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice at the level of the aortic root after staining with Oil Red O. ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice had smaller lesions than ApoE<sup>-/-</sup> mice at 15 weeks of age (ApoE<sup>-/-</sup> versus ApoE<sup>-/-</sup>Irf5<sup>-/-</sup>: 7.2% [IQR, 5.99–7.91] versus 4.44% [IQR, 2.99–6.48]; *P*=0.084). Similarly, IRF5-deficient ApoE<sup>-/-</sup> mice had smaller lesions at 20 weeks of age (11.9% [IQR, 11.2–16.3] versus 9.5% [IQR, 7.85–10.7]; *P*=0.032; [Figure 1A](#)). No difference was observed at 27 weeks of age. The smaller lesion size was accompanied by a reduction in necrotic core formation, evaluated using hematoxylin and eosin staining according to established protocols.<sup>18</sup> In contrast to ApoE<sup>-/-</sup> mice,

lesional necrotic core size was  $\approx 70\%$  smaller in ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice at 20 weeks of age (20.4% [IQR, 16.7–27.9] versus 6.14% [IQR, 5.63–10.3];  $P=0.0023$ ) and  $\approx 73\%$  smaller at 27 weeks of age (32.9% [IQR, 29.7–36.3] versus 9% [IQR, 7.5–13.1];  $P=6.5 \times 10^{-5}$ ; Figure 1B).

Lesions in the aortic root were further characterized by immunohistochemistry. A small increase in CD68 (Figure 2A) immunopositive area percentage was observed in the ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice across all the time points ( $P=0.045$ ; Table II in the online-only Data Supplement). However, this difference did not achieve statistical significance in the planned tests conducted at the individual time points or when CD68 immunopositivity was expressed as absolute area.

CD11c<sup>+</sup> myeloid cells contribute to lipid accumulation and the initiation of atherosclerosis.<sup>19</sup> Hence, CD11c expression was examined. CD11c expression was significantly attenuated in aortic root lesions of ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice with a 57% decrease at 20 weeks of age (8.65% [IQR, 5.8–10] versus 3.7% [IQR, 2.3–4.1];  $P=0.0092$ ) and an 80% reduction at 27 weeks of age (10.2% [IQR, 5.8–12.8] versus 2.1% [IQR, 1.5–2.2];  $P=0.0028$ ) (Figure 2B). Conversely, a trend towards an increase in lesional smooth muscle cell  $\alpha$ -actin content was seen in ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice at 27 weeks of age ( $P=0.052$ ; Figure IIA in the online-only Data Supplement).

### IRF5 Deletion in Hypercholesterolemic Mice Modulates Macrophage Markers in Atherosclerotic Lesions

Necrotic core development is strongly related to the behavior of myeloid cell populations in particular macrophages.<sup>20</sup> IRF5 defines a proinflammatory macrophage phenotype.<sup>8</sup> Both proinflammatory and alternatively activated macrophages have been identified in atherosclerotic lesions.<sup>21,22</sup> Thus, we investigated whether IRF5 deletion affected the expression of macrophage markers within atherosclerotic plaques. Lesions were stained for the proinflammatory macrophage marker inducible nitric oxide synthase (iNOS), the alternatively activated macrophage marker CD206 (mannose receptor), and the lipid/heme driven Mox/Mhem macrophage marker heme oxygenase-1. Heme oxygenase-1 expression was significantly upregulated in the aortic root lesions of 15-week-old ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice ( $P=0.002$ ; Figure IIB in the online-only Data Supplement), as was lesional CD206 expression at 27 weeks of age ( $P=0.030$ ; Figure 2C). No difference in lesional iNOS protein expression was seen at the time points studied by immunohistochemistry (Figure IIC in the online-only Data Supplement).

To investigate the modification of myeloid cell programming in the lesions, gene expression levels of a

bespoke panel of myeloid markers were quantified in the aortic arch of 20-week-old mice, the time point at which the maximum difference in lesion size between ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice was observed. The levels of gene expression of *Itgax* (CD11c;  $P=1 \times 10^{-6}$ ), *Cd68* ( $P=0.0016$ ), *Nos2* ( $P=0.0016$ ), and tumor necrosis factor- $\alpha$  ( $P=0.0017$ ) were significantly reduced in the aorta of ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice, whereas *Irf4* ( $P=0.0023$ ) and *Il4* ( $P=5 \times 10^{-5}$ ), were up-regulated (Figure 3A). A similar pattern of gene expression was found in the aorta at 27 weeks of age (Figure 3B) and the PALNs (situated by the iliac bifurcation, a common site of atherosclerotic plaque development; Figure 3C).

### IRF5 Deficiency Reduces Shear Stress-Modulated Plaque Vulnerability


A perivascular shear stress-altering cast, which is surgically tied around the carotid artery of ApoE<sup>-/-</sup> mice, has been shown to mimic human shear stress patterns and generates atherosclerotic lesions with TCFA morphology in mice. In this model, LSS induces macrophage-rich vulnerable plaques, and oscillatory shear stress (OSS) produces smooth muscle cell-rich stable plaques.<sup>14</sup> We previously showed that IRF5 expression is enhanced at the LSS-exposed region of the carotid artery, in keeping with higher expression of inflammatory macrophage markers, including iNOS at this site.<sup>15</sup>

To investigate whether IRF5 modulates plaque size and composition in a murine model of TCFA, ApoE<sup>-/-</sup>, and ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice were fed a high-fat diet for 2 weeks before undergoing surgery to place the perivascular shear stress-modifying cast. Animals were euthanized and casts removed after 9 weeks. ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice fed a high-fat diet were found to be significantly heavier than ApoE<sup>-/-</sup> mice (Table VII in the online-only Data Supplement) as previously published.<sup>10</sup> However, no differences in serum cholesterol levels were detected between the 2 groups (Table VII in the online-only Data Supplement).

No statistically significant differences were shown in lesion size between the 2 genotypes after cast placement (Figure III in the online-only Data Supplement). The size of the necrotic core in the lesions induced by LSS was significantly smaller in ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice (27.9% [IQR, 23–35.1] versus 5.65% [IQR, 4.93–6.83];  $P=0.00062$ ; Figure 4A), whereas no difference in necrotic core size of lesions in the OSS region was observed between the 2 genotypes. No differences were observed in the expression of CD68 (Figure 4B), iNOS, CD206, or heme oxygenase-1 (Table VIII in the online-only Data Supplement).

CD11c expression was almost abrogated in both LSS- and OSS-modulated regions of the ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> carotid compared with ApoE<sup>-/-</sup> mice (LSS: 6.41% [IQR, 5.35–





**Figure 1. IRF5 deficiency decreases lesion and necrotic core size in the aortic root of ApoE<sup>-/-</sup> mice.**

Representative images of aortic root sections from ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice 15, 20, or 27 weeks of age stained with Oil Red O and hematoxylin for lesion area (A). Graphs show cross-sectional aortic root lesion area ( $\times 10^3 \mu\text{m}^2$  and %) (B) hematoxylin and eosin for necrotic core delineation. Graphs show aortic root lesional necrotic core area (defined as anuclear, afibrotic, and eosin-negative areas) ( $\times 10^3 \mu\text{m}^2$  and %). Dotted lines show necrotic core area. Each circle represents the mean area per individual mouse. Horizontal line denotes group median (n=9 to 10). Bars=100 $\mu\text{m}$ . ApoE indicates apolipoprotein E-deficient; and IRF, interferon regulatory factor. \* $P<0.05$ ; \*\* $P<0.01$ ; \*\*\* $P<0.001$ .

8.17] versus 0.07% [IQR, 0.045–0.097];  $P=0.0036$ ; OSS: 4.09% [IQR, 2.04–5.48] versus 0.06% [IQR, 0.027–0.125];  $P=0.0037$ ; Figure 4C). It is important to note that IRF5 deficiency increased the smooth muscle cell content in the LSS region ( $P=0.029$ ; Figure 4D).

### IRF5 Deficiency Reduces CD11c Expression in the Aorta, Draining Lymph Nodes, and Bone Marrow Cultures

A reduction in CD11c expression observed by both immunohistochemistry and gene expression quantification emerged as the most striking change in myeloid markers induced by IRF5 deficiency in vivo. To assess whether differences in gene expression reflected changes in specific cell populations, 8-color flow cytometry was performed on aortas, PALNs, and in vitro GM-CSF-derived bone marrow-derived cell cultures from ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice. In line with the gene expression data, ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice showed a significant decrease in CD11c-expressing F4/80<sup>+</sup>CD11b<sup>+</sup> and F4/80<sup>+</sup>CD11b<sup>+</sup>MerTK<sup>+</sup> macrophages in the aorta and PALNs (Figure 5A and 5B and Figures IV and V in the online-only Data Supplement) compared to ApoE<sup>-/-</sup> mice. There was also a decrease in the comparatively small CD11b<sup>+</sup> dendritic cell population ( $P<0.05$ ; Figure

VI in the online-only Data Supplement). However, there was no change in CD103<sup>+</sup> dendritic cells in the aorta of ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice (Figure VI in the online-only Data Supplement). Attenuation of CD11c<sup>+</sup> macrophage frequencies in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice was also confirmed in GM-CSF-derived bone marrow cell cultures ( $P<0.05$ ; Figure 5C).

Chromatin immunoprecipitation revealed specific binding of IRF5 to the promoter region of *Itgax* (Figure 6A). Notably, the binding of IRF5 to the CD11c gene loci was dependent on lipopolysaccharide (LPS) stimulation, with recruitment of IRF5, as detected by peak calling with MACS2, occurring in stimulated macrophages but not in untreated cells. This finding is in keeping with the key role of IRF5 as a stimulus-dependent transcription factor in the macrophage immune response. Next we aimed to investigate whether IRF5 regulates the expression of CD11c in GM-CSF-matured macrophages. The levels of *Itgax* (CD11c) expression were significantly reduced in LPS-treated GM-CSF-cultured bone marrow-derived macrophages deficient in IRF5 ( $P<0.05$ ; Figure 6B).

Next we explored the coexpression of IRF5 and CD11c within human atherosclerotic plaques. The expression of IRF5 and CD11c was assessed histologically in human carotid plaques from the Carotid Plaque Imag-




**A**, Representative photomicrographs of aortic root sections from 15-, 20-, and 27-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice stained with an antibody against CD68 (brown staining) and hematoxylin. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu\text{m}^2$  and %) for CD68. **B**, Representative photomicrographs of aortic root sections from 15-, 20-, and 27-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice stained with an antibody against CD11c (brown staining) and hematoxylin. Arrows highlight CD11c<sup>+</sup> positive cells. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu\text{m}^2$  and %) for CD11c. **C**, Representative photomicrographs of aortic root sections from 15-, 20-, and 27-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice stained with an antibody against CD206 (brown staining) and hematoxylin. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu\text{m}^2$  and %) for CD206 (n=9 to 10). Bars=100 $\mu\text{m}$ . Each circle represents the mean positive area per individual mouse. Horizontal line denotes group median. ApoE indicates apolipoprotein E-deficient; and IRF, interferon regulatory factor. \* $P<0.05$ ; \*\* $P<0.01$ ; \*\*\* $P<0.001$ .

crotic area and CD11c<sup>+</sup> myeloid cell content. Next, we explored the mechanistic relationship between these 2 observations by investigating whether IRF5 deficiency affected the functional behavior of myeloid cells in mice with hypercholesterolemia.

Bone marrow-derived cells were cultured in the presence of GM-CSF before being magnetically sorted into CD11c<sup>+</sup> and CD11c<sup>-</sup> populations. The cells were then left unstimulated or activated with LPS. We investigated whether *Irf5* deficiency modifies the phagocytosis and foam cell formation capacity of myeloid cells. The GM-CSF-cultured CD11c<sup>+</sup> or CD11c<sup>-</sup> bone marrow cells were incubated with fluorescently labeled acetylated human low-density lipoprotein or fluorescent microspheres to assess their phagocytosis efficiency. IRF5 deficiency did not affect the ability of the bone

Our data demonstrate that IRF5 deficiency in mice with hypercholesterolemia reduces both the intralesional ne-



**Figure 3. Decreased gene expression of inflammatory and myeloid cell markers in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice.**

The aortic arches and PALNs of ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice were collected and RNA extracted. Gene expression of inflammatory and myeloid cell markers was then assessed by reverse transcription polymerase chain reaction. **A** and **B**, Graphs show gene expression of selected genes in the aortic arch of ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice (white bars) at 20 (**A**) and 27 (**B**) weeks of age. **C**, Graph shows gene expression of selected genes in the PALN of ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice (white bars) at 20 weeks of age. Data are presented as fold change (n=8). Bars=mean+SEM. ApoE indicates apolipoprotein E-deficient; IRF, interferon regulatory factor; and PALN, para-aortic lymph nodes. \*\**P*<0.01; \*\*\**P*<0.001.

marrow-derived cells to take up fluorescently labeled acetylated human low-density lipoprotein and become foam cells, nor did it affect their ability to perform bead phagocytosis (Tables IX and X in the online-only Data Supplement).

The amount of cell apoptosis is an important factor in necrotic core formation.<sup>23</sup> Apoptosis was induced with ultraviolet light, cells were stained with propidium iodide and Annexin V, and apoptosis levels were measured by flow cytometry. It is interesting to note that late apoptosis was decreased in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> CD11c<sup>+</sup> cells after activation with LPS (*P*<0.0001; Figure 7A and Table XI in the online-only Data Supplement).

Finally, the ability to perform apoptotic cell removal (efferocytosis) was examined by incubating the bone marrow-derived cells with fluorescently labeled apoptotic Jurkat cells as previously published.<sup>18</sup> The efficiency of efferocytosis by GM-CSF differentiated ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> CD11c<sup>+</sup> cells was ~30% higher than that of differentiated ApoE<sup>-/-</sup> CD11c<sup>+</sup> cells (*P*<0.0001; Figure 7B).

To investigate whether the effect of IRF5 deficiency on efferocytosis was also observable in situ, carotid plaque sections were costained for apoptosis with TUNEL stain and CD68 using previously described methods.<sup>24</sup> In support of the in vitro data, the frequency of apoptotic cells was decreased in situ in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice (*P*=0.04; Figure 7C). Conversely, the percentage of

apoptotic cells undergoing efferocytosis was enhanced in plaque tissue obtained from IRF5-deficient ApoE<sup>-/-</sup> mice (*P*=0.001; Figure 7C).


In summary, IRF5 deficiency promotes the viability of CD11c<sup>+</sup> GM-CSF-derived bone marrow macrophages and their ability to perform efferocytosis, but it does not affect their ability to phagocytose lipid or beads.

### IRF5 Suppresses Efferocytosis-Regulating Genes In Vitro and In Situ

To further explore how IRF5 may interfere with myeloid cell capacity to perform efferocytosis, gene expression of the most characterized receptors for efferocytosis, the TAM (Tyro3, Axl, and Mer) receptors tyrosine-protein kinase Mer (MerTK), Axl, and Tyro3, as well as Itgb3 (which forms the  $\alpha_v\beta_3$  receptor with alpha 5 integrin), were analyzed in GM-CSF-matured bone marrow-derived myeloid cell cultures.

GM-CSF-matured cells from ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice displayed significantly higher gene expression of Itgb3 compared with cells from ApoE<sup>-/-</sup> mice (*P*=0.0037; Figure 8A). A small increase in Tyro3 expression was also found (*P*=0.013; Figure 8A), whereas no effect on the gene expression of MerTK or Axl was observed. Since in vitro-matured cells may not always reflect the phenotype of cells matured in vivo, we next assessed the ex-





**Figure 4. IRF5 deficiency decreases necrotic core formation and CD11c expression in shear stress-modulated lesions.**

ApoE<sup>-/-</sup> (black circles) and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice (white circles) were placed on a high-fat diet at 17 to 18 weeks of age. After 2 weeks, a perivascular shear stress-altering cast was surgically placed around the common carotid artery and left in place for 9 weeks. **A**, Representative photomicrographs of carotid artery sections stained with hematoxylin and eosin. Graphs show lesional necrotic core area (defined as anuclear, afibrotic, and eosin-negative areas) (x1000 μm<sup>2</sup> and %). Solid lines show necrotic core area. **B**, Representative photomicrographs of carotid sections stained with an antibody against CD68 (brown staining) and hematoxylin. Graphs show lesion area staining positive (x1000 μm<sup>2</sup> and %) for CD68. Dotted lines denote lesion area. **C**, Representative photomicrographs of carotid sections stained with an antibody against CD11c (brown staining) and hematoxylin. Graphs show lesion area staining positive (x1000 μm<sup>2</sup> and %) for CD11c. Dotted lines denote lesion area. **D**, Representative photomicrographs of carotid sections with an antibody against smooth muscle cell α-actin (ASMA) (Cy3-red). Graphs show aortic root lesion area staining positive (x1000 μm<sup>2</sup> and %) for ASMA. Dotted lines denote lumen. Bars=100 μm in **A** through **C** and 80 μm in **D** (n=8). Each circle represents the mean positive area per individual mouse. Horizontal line denotes group median. ApoE indicates apolipoprotein E-deficient; IRF, interferon regulatory factor; and SMC, smooth muscle cell. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001.


pression of efferocytosis-regulating genes in the aortas of ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice. Again, Itgb3 expression was significantly higher in the aortas of ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice (P=0.0006; Figure 8B). The increase in Itgb3 gene expression in IRF5-deficient ApoE<sup>-/-</sup> mice was also confirmed at the level of cell surface protein expression using flow cytometry (P<0.05; Figure 8C). It is important to note that the increase in Itgb3 was restricted to CD11c<sup>-</sup> macrophages, in keeping with the results of the functional efferocytosis assays.

We next assessed gene expression of the ligand of α<sub>v</sub>β<sub>3</sub>, Mfge8, and the ligands for the TAM receptors: growth arrest-specific 6 and protein S in GM-CSF-

derived bone marrow myeloid cells. The gene expression of Mfge8 was found to be significantly higher in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice (P=0.0085; Figure 8A). This increase in Mfge8 gene expression was also present in the aorta of ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice (P=0.01; Figure 8B). No differences in gene expression of the TAM receptors ligands growth arrest-specific 6 or protein S were found between ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice in vitro or in situ (Figure 8A and 8B).

Since Mfge8 acts as a ligand between α<sub>v</sub>β<sub>3</sub> and phosphatidylserine on apoptotic cells, the secretion of the protein is crucial for its effects in the lesion. Herein, Mfge8 levels were analyzed in supernatants of the





**Figure 5. IRF5 affects myeloid cell phenotype in the aorta, para-aortic lymph nodes, and in vitro bone marrow cultures.**

Aortas, PALNs, and bones were harvested from 20- to 24-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice. Single-cell suspensions were then stained with antibodies against myeloid cell markers and analyzed by flow cytometry. Dead cells and debris were excluded from the analysis, and cells were gated on CD45<sup>+</sup> cells. **A**, Graphs show the numbers of aortic CD11c<sup>+</sup> macrophages (gated as CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup> cells or as CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup>MerTK<sup>+</sup>), expressed as a percentage of CD45<sup>+</sup> cells (n=8). **B**, Graphs show the numbers of CD11c<sup>+</sup> macrophages in the PALNs, expressed as a percentage of CD45<sup>+</sup> cells (n=8). **C**, Graphs show the numbers of CD11c<sup>+</sup>- and CD11c<sup>-</sup>-expressing macrophages in GM-CSF-derived macrophage cultures in vitro, expressed as a percentage of CD45<sup>+</sup> cells (n=4). Each circle represents an individual mouse. Horizontal line denotes group mean. ApoE indicates apolipoprotein E-deficient; IRF, interferon regulatory factor; MerTK, tyrosine-protein kinase Mer; and PALN, para-aortic lymph nodes. \*P<0.05.

in vitro bone marrow cell cultures. Mfge8 levels were found to be significantly higher in the supernatants from ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup>-derived cells cultured in GM-CSF (P=0.005; Figure 8D).

To investigate whether the enhanced capacity to perform efferocytosis in Irf5-deficient macrophages was Itgb3 or Mfge8 dependent, additional knockdown experiments were performed. Using siRNA, Mfge8 and Itgb3 were knocked down in GM-CSF-derived bone marrow-derived macrophages from Irf5-deficient and

Irf5-competent ApoE<sup>-/-</sup> mice. The increase in Itgb3 and Mfge8 gene expression in Irf5-deficient compared with Irf5-competent ApoE<sup>-/-</sup> mice was confirmed in the control siRNA conditions (P<0.05 and P<0.01, respectively; Figure 8E). Next, the effect of siRNA knockdown was assessed using quantitative reverse transcription polymerase chain reaction. The gene expression of both Itgb3 and Mfge8 were confirmed to be significantly suppressed in IRF5-deficient macrophages after siRNA transfection (P<0.05 and P<0.001, respectively; Figure 8E). Using flow cytometry, knockdown of Itgb3 was confirmed in IRF5-deficient macrophages at the protein level (Figure 8F).


To assess whether the knockdown of Itgb3 or Mfge8 affected the efferocytosis capacity of Irf5-deficient macrophages, the in vitro efferocytosis assay was repeated. A significantly increased efferocytosis capacity in the uptake of apoptotic Jurkat cells in the Irf5-deficient group compared with the Irf5-competent group was confirmed in the siRNA control groups (37.7% ± 5.4% versus 60.3% ± 8.3%, P<0.05; Figure 8G). Knockdown of either Itgb3 or Mfge8 decreased the efferocytic ability and thus reversed the in vitro phenotype of the IRF5-deficient macrophages to the level of those from IRF5-competent mice (60.3% ± 8.3% versus 28.8% ± 6.4%, P<0.01 and 60.3% ± 8.3% versus 27.6% ± 2.6%, P<0.01; Figure 8G).

## DISCUSSION

Myeloid cells are powerful contributors to the development and complications of atherosclerosis. IRF5 is a master regulator of myeloid cell function and programming in mouse and human.<sup>8</sup> We show that IRF5 deletion in ApoE<sup>-/-</sup> mice reduces aortic atherosclerotic lesion size and also decreases the expression of the integrin CD11c in both macrophages and atherosclerotic lesions. In sharp contrast, IRF5 deficiency enhances both the expression of the integrin Itgb3 and its bridging ligand Mfge8 and the ability of myeloid cells to perform efferocytosis. This finding leads to a significant decrease in the necrotic core size in aortic atherosclerosis and LSS-induced TCFA lesions, demonstrating that IRF5 is instrumental in necrotic core formation.

### IRF5 Affects the Lesional Content of CD11c<sup>+</sup> Macrophages

CD11c<sup>+</sup> myeloid cells are present in the arterial wall at athero-susceptible sites exposed to alterations in hemodynamic stress, such as curvatures and bifurcations.<sup>25</sup> CD11c expression by monocytes is upregulated by hypercholesterolemia,<sup>26</sup> and depletion of CD11c<sup>+</sup> cells has been shown to reduce atherogenesis in ApoE<sup>-/-</sup> mice.<sup>19,26</sup> Collectively, these studies indicate



**Figure 6. IRF5 regulates CD11c expression.**


**A**, Chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) of IRF5 binding sites from unstimulated and LPS-stimulated GM-CSF bone marrow-derived cells revealed specific binding of the transcription factor to the promoter region of ITGAX in GM-CSF-cultured bone marrow-derived macrophages. Notably, the binding of IRF5 to the ITGAX gene loci is dependent on LPS stimulation, with recruitment of IRF5, as detected by peak calling with MACS2, occurring in stimulated macrophages but not in untreated cells. **B**, Graph shows the fold change of CD11c gene expression in unstimulated or LPS-stimulated GM-CSF bone marrow-derived cells from ApoE<sup>-/-</sup> (black bars) or ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> (white bars) mice. CD11c gene expression is downregulated in GM-CSF-matured bone marrow-derived macrophages from IRF5-deficient mice upon LPS stimulation (n=6 to 10). Data are presented as mean±SEM. ApoE indicates apolipoprotein E-deficient; GM-CSF, granulocyte-macrophage colony-stimulating factor; IRF, interferon regulatory factor; Itgb3, integrin-β3; and LPS, lipopolysaccharide. \*P<0.05.

the existence of proatherogenic CD11c<sup>+</sup> myeloid cell populations.

In the present study, we observed a significant reduction in lesional CD11c staining in the absence of IRF5 in both hypercholesterolemia-induced and LSS-induced murine atherosclerosis models. Using flow cytometry to pinpoint the specific cell subsets affected by IRF5 deficiency, we were able to show a reduction in CD11c<sup>+</sup> macrophages in the aortic lesions and draining lymph nodes. The reduction in CD11c expression was confirmed at the gene level in aortas and PALNs from IRF5-deficient ApoE<sup>-/-</sup> mice. Loss of CD11c was also evident in vitro in IRF5-deficient GM-CSF-matured macrophages. In a chromatin immunoprecipitation sequencing survey of genome-wide IRF5 binding sites in GM-CSF cultured bone marrow-derived macrophages, a specific binding

site was revealed in the promoter region of the *Itgax* (CD11c) gene. In addition, the level of CD11c gene expression was significantly reduced in macrophages derived from IRF5-deficient ApoE<sup>-/-</sup> mice upon LPS stimulation. These data suggest that on activation IRF5 directly regulates the gene expression of CD11c in macrophages.

We have previously shown that IRF5 promotes an inflammatory macrophage phenotype by direct regulation of selected cytokines and surface receptors,<sup>8,10,11,17</sup> and it is now widely used as a marker of inflammatory macrophages.<sup>27,28</sup> This study adds *Itgax* (CD11c) to the list of IRF5-regulated markers that define an inflammatory macrophage phenotype. The involvement of the integrin CD11c in cell adhesion,<sup>29</sup> monocyte/macrophage recruitment,<sup>26</sup> and modulation of IL-1 production<sup>30</sup> is well documented in the context of atherosclerosis.



**Figure 7. IRF5 deficiency reduces cellular apoptosis and increases efferocytosis.**

Bone marrow cells from ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> (white bars) mice 16 to 20 weeks of age were cultured in GM-CSF for 7 days, and their ability to undergo apoptosis and to perform efferocytosis was assessed. **A**, Graph shows percentage of CD11c<sup>+</sup> and CD11c<sup>-</sup> cells staining positive for propidium iodide and Annexin V after LPS stimulation and ultraviolet light exposure (n=8). **B**, Graph shows percentage of apoptotic Jurkat cell uptake by CD11c<sup>+</sup> and CD11c<sup>-</sup> macrophages (n=8). **C**, Representative images of perivascular flow-modifying cast-induced carotid lesions in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice stained with an antibody against CD68 (red) and TUNEL stained (green) and DNA (blue). Graphs show number of apoptotic cells (left) and percentage (right) of apoptotic cells undergoing efferocytosis in situ (n=4 to 5). Data are presented as mean±SEM. Black bars, ApoE<sup>-/-</sup>. White bars, ApoE<sup>-/-</sup>Irf5<sup>-/-</sup>. ApoE indicates apolipoprotein E-deficient; and IRF5, interferon regulatory factor. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001.

The expression of CD11c has previously been shown to associate with proinflammatory macrophage phenotype in obesity.<sup>31</sup> Loss of aortic CD11c gene expression in IRF5-deficient mice was associated with a reduction in the aortic expression of proinflammatory genes such as iNOS and tumor necrosis factor- $\alpha$ , and an increase in genes associated with alternatively activated macrophages such as interleukin 4 and IRF4, indicating that IRF5 is responsible for a shift toward a proinflammatory myeloid cell programming in atherosclerosis. IRF5 induced other changes in macrophage phenotype in a time-dependent manner. At early stages of disease, heme oxygenase-1 expression was increased in lesions of ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> compared with ApoE<sup>-/-</sup> mice, whereas at more advanced stages, CD206 expression was increased in ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> lesions. The change in CD206 expression fits with the observed increase in gene expression of M2-inducing interleukin 4 and IRF4 in the aorta. Our data indicate that CD11c expression is the hallmark of an IRF5-dependent subset of macrophages with a detrimental role in atherosclerosis.

GM-CSF is a strong inducer of IRF5 expression.<sup>8</sup> Our data show that IRF5 deletion decreases the representation of CD11c<sup>+</sup> bone marrow-derived myeloid cells after differentiation with GM-CSF. This observation is in keeping with previous studies reporting that GM-CSF has an important role in the maintenance of CD11c<sup>+</sup> myeloid cells in atherosclerosis.<sup>32</sup>


In support of our findings in murine atherosclerosis, a significant association between IRF5 and CD11c expression was also found in human atherosclerotic tissue (Figure VIIA in the online-only Data Supplement). IRF5

gene expression has previously been shown to be increased in human atherosclerotic tissue compared with control tissue, but less is known about the potential effects of IRF5 activity in human plaque biology.<sup>33</sup> The present findings support a role for IRF5 as an important transcription factor, potentially supporting an inflammatory macrophage subset identifiable by the expression of CD11c in human disease.

Collectively, our data indicate that IRF5 is an important factor for the maintenance of CD11c<sup>+</sup> myeloid cell populations within atherosclerotic lesions and also directly regulates the expression of CD11c on macrophages.

### IRF5 Increases Necrotic Core Size by Impairing Myeloid Cell Efferocytosis

The association between IRF5 and efferocytosis has not been previously described. In the present study, we show that IRF5 deficiency is associated with decreased necrotic core size, in both a standard hypercholesterolemia-driven model and a shear stress-modulating surgical model known to form TCFA.<sup>15</sup> The necrotic core in atherosclerotic plaques arises because of a combination of macrophage apoptosis and defective efferocytosis (uptake of apoptotic cells).<sup>5</sup> The capacity of macrophages to perform efferocytosis and phagocytosis is thought to be broadly dependent on their activation and polarization status, with efferocytosis being inhibited by tumor necrosis factor- $\alpha$ <sup>34,35</sup> and enhanced by interleukin 4/interleukin 13 and peroxisome proliferator-activated receptor- $\gamma$  signaling.<sup>21,36</sup> The dysregulated



**Figure 8. IRF5 deficiency increases efferocytosis by CD11c<sup>+</sup> cells by an upregulation of Itgb3 and Mfge8.**

**A**, Gene expression (shown as fold change) of efferocytosis regulating receptors (*Itgb3*, *MerTK*, *Axl*, and *Tyro3*) and efferocytosis-regulating bridging molecules (*Mfge8*, *Gas6*, and *Protein S*) in GM-CSF-matured macrophage cell cultures from ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> (white bars) mice 16 to 20 weeks of age (n=6 to 8). Data presented as median and IQR. **B**, Gene expression (shown as fold change) of efferocytosis-regulating receptors (*Itgb3*, *MerTK*, *Tyro3*, *CD36*, and *CD14*) and receptor ligands (*Mfge8*, *Gas6*, and *Protein S*) in the aorta of 20-week-old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> mice (n=5 to 8). Data presented as median and IQR. **C**, CD11c<sup>+</sup> GM-CSF-matured macrophages from ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> mice were stained with an antibody against Itgb3. Representative plots show Itgb3 expression on CD11c<sup>+</sup> cells and graphs show numbers (left) of CD11c<sup>+</sup> cells expressing Itgb3 and the median fluorescent intensity (MFI) of Itgb3 staining (right) (n=6). Horizontal bars denote group median. **D**, Bone marrow-derived cells from ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> mice were cultured in GM-CSF for 7 days, and Mfge8 released into the supernatant was assessed by ELISA (n=8). Data are presented as median and IQR. **E**, Gene expression level (fold change) of Itgb3 (left) and Mfge8 (right) in GM-CSF-matured macrophages from ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> (white bars) mice after transfection with siRNA against Itgb3, Mfge8, or a control siRNA. Graphs show mean and SEM (n=3). **F**, Histogram overlay of Itgb3 protein expression, as assessed by flow cytometry, on GM-CSF-matured macrophages after transfection with siRNA against Itgb3 (red) or control (blue). **G**, Percentage of apoptotic Jurkat cell uptake by GM-CSF-cultured macrophages from ApoE<sup>-/-</sup> (black bars) and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> (white bars) mice after transfection with siRNA against Itgb3, Mfge8, or a control siRNA. Graphs show mean and SEM (n=4). ApoE indicates apolipoprotein E-deficient; Ctrl, control; GM-CSF, granulocyte-macrophage colony-stimulating factor; IRF, interferon regulatory factor; Itgb3, integrin- $\beta$ 3; MerTK, tyrosine-protein kinase Mer; and Mfge8, milk fat globule-epidermal growth factor 8 protein. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

inflammation present in advanced lesions is thought to play a role in disabling efferocytosis.<sup>20</sup> However, the specific transcriptional regulators impairing efferocytosis in atherosclerosis are poorly defined.

IRF5 deletion uncovered a complex interaction between CD11c expression and myeloid cell capacity to perform efferocytosis. Isolated CD11c<sup>+</sup> cells from GM-CSF-derived bone marrow cultures from IRF5-deficient ApoE<sup>-/-</sup> mice performed efferocytosis to a significantly greater extent than CD11c<sup>+</sup> cells from IRF5-competent ApoE<sup>-/-</sup> mice. Furthermore, IRF5 deletion selectively affected macrophage efferocytosis and did not interfere

with phagocytosis or lipid uptake functions, suggesting that IRF5 plays a selective role in efferocytosis. Our data support the concept that macrophage programming consists of modules that can be activated independently of others rather than an en bloc phenotype.

The mechanism of efferocytosis is dependent on specific receptors and bridging molecules and is distinct from phagocytosis. Efferocytosis prevents secondary necrosis and is crucial for regulating and resolving the inflammatory response in atherosclerotic lesions.<sup>20</sup> Because IRF5 clearly affected the ability of CD11c<sup>+</sup> cells to perform efferocytosis, we sought to identify potential



efferocytosis pathways that *Irf5* may regulate. MerTK is a member of the TAM receptor tyrosine kinases that have important functions in efferocytosis and regulation of innate immunity.<sup>37</sup> Defective efferocytosis induced by the deletion of MerTK accelerates atherosclerosis and necrotic core formation.<sup>24</sup> However, in our study, MerTK<sup>+</sup> macrophages were decreased in lesions in ApoE<sup>-/-</sup>*Irf5*<sup>-/-</sup> mice. This finding is in keeping with a recent article by Cai et al,<sup>7</sup> which highlighted that proteolytic cleavage of MerTK occurs in atherosclerosis and supports necrotic core formation. The lack of enhancement of MerTK protein expression in IRF5-deficient mice suggested that other efferocytosis pathways were at play.

The  $\alpha_v\beta_3$  integrin is known to be a powerful mediator of efferocytosis through binding to phosphatidylserine on apoptotic cells by the bridging molecule Mfge8. Itgb3 is one of the regulating parts of the  $\alpha_v\beta_3$  integrin.<sup>38</sup> Mfge8 is a glycoprotein secreted by macrophages that binds strongly to cells expressing  $\alpha_v\beta_3$  integrin. Depleting Mfge8 inhibits efferocytosis, and Mfge8 deficiency in atherosclerosis models accelerates atherosclerosis and leads to the accumulation of apoptotic cells.<sup>38,39</sup> However, the role of Itgb3 on atherosclerotic efferocytosis has been less well described, and a role for IRF5 in regulating Itgb3 has not previously been shown. Both Itgb3 and its ligand Mfge8 were significantly upregulated in both the aorta and GM-CSF-derived cells from IRF5-deficient ApoE<sup>-/-</sup> mice. Moreover, when Itgb3 and Mfge8 were knocked down, the efferocytic phenotype of the IRF5-deficient cells was reversed, suggesting that the Mfge8–Itgb3 pathway was responsible for the increased ability of IRF5-deficient macrophages to perform efferocytosis. In summary, we provide evidence for an important role of *Irf5* in impairing efferocytosis through the reduction of expression of Itgb3 and Mfge8.

Deletion of IRF5 might affect intralésional macrophage content through mechanisms other than efferocytosis. Macrophages from IRF5-deficient ApoE<sup>-/-</sup> mice were resistant to apoptosis in vitro, and this observation is supported by intralésional TUNEL staining. In keeping with this observation, we observed a small increase in the CD68 immunopositive area percentage across all time points. Thus, the effect of IRF5 deletion on lesional CD68<sup>+</sup> cell content could possibly be explained by the complex role of IRF5 in cell survival and efferocytosis.

Our data reveal that IRF5 deletion has a significant effect on macrophage phenotype and function in atherosclerosis. IRF5 is expressed by monocytes, macrophages, conventional dendritic cells, plasmacytoid dendritic cells, B cells, and some stromal cells.<sup>40</sup> Although the expression of IRF5 within mouse and human atherosclerotic lesions appeared to be confined to myeloid cells, our data (obtained with a global genetic deletion of IRF5) cannot exclude indirect effects arising from the deletion of IRF5 in other cell types and thus is a limitation of our study.

## CONCLUSIONS

In summary, the transcription factor *Irf5* has a detrimental effect in atherosclerosis by affecting plaque formation and stability through the modulation of macrophage phenotype and function. IRF5 activation directly regulates expression of the integrin CD11c on macrophages and promotes the maintenance of pro-inflammatory CD11c<sup>+</sup> macrophages within the lesions. Moreover, IRF5 actively contributes to the impairment of efferocytosis, and its deletion ameliorates the formation of the necrotic core by the upregulation of the integrin Itgb3 and its ligand Mfge8 (Figure VIII in the online-only Data Supplement). Our study highlights the existence of equilibrium between CD11c<sup>+</sup> and CD11c<sup>-</sup> Itgb3<sup>+</sup> macrophage subsets within atherosclerotic lesions, which significantly impacts the formation of the necrotic core.

## SOURCES OF FUNDING

The research leading to these results has received funding from the British Heart Foundation Center of Research Excellence, Imperial College London, the European Commission under the Seventh Framework Program (FP7/2007–2013; contract no. 201668; AtheroRemo and HEALTH.2012-1.2-1; contract no. 305739 RiskyCAD), The Kennedy Trustees, The Swedish Heart and Lung foundation (20150277), The Swedish Research Council (2015-00582), the Swedish Society of Medicine (SLS-500141), Skåne University Hospital funds, Region Skåne Research funds, and the Novo Nordisk Foundation (grant no. NNF15CC0018346).

## DISCLOSURES

None.

## AFFILIATIONS

From Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom (A.N.S., A.E., J.E.C., C.K., M.S., I.P., P.G., T.K., D.S., M.E.G., S.N.S., I.A.U., C.M.); Department of Bioengineering, Imperial College London, United Kingdom (A.N.S., R.K.); Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Sweden (A.E., I.G.); Department of Cardiology, Skåne University Hospital, Lund/Malmö, Sweden (A.E., I.G.); and School of Engineering and Materials Science, Queen Mary University of London, United Kingdom (R.K.).

## FOOTNOTES

Received February 10, 2017; accepted June 13, 2017.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.027844/-DC1>.

*Circulation* is available at <http://circ.ahajournals.org>.

## REFERENCES

- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzi M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasserli K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwelb DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0.
- Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol Cell*. 1998;2:275–281.
- Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, Imes S, Fishbein MC, Clinton SK, Libby P, Lusis AJ, Rajavashisth TB. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. *Am J Pathol*. 1997;150:1687–1699.
- Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. *Nat Rev Cardiol*. 2015;12:10–17. doi: 10.1038/nrcardio.2014.173.
- Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. *Cell*. 2011;145:341–355. doi: 10.1016/j.cell.2011.04.005.
- Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Drenzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, Leeper NJ. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. *Nature*. 2016;536:86–90. doi: 10.1038/nature18935.
- Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G, Tabas I. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. *Proc Natl Acad Sci U S A*. 2016;113:6526–6531. doi: 10.1073/pnas.1524292113.
- Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Husell T, Feldmann M, Udolova IA. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nat Immunol*. 2011;12:231–238. doi: 10.1038/ni.1990.
- Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. *Nature*. 2005;434:243–249. doi: 10.1038/nature03308.
- Dalmas E, Toubal A, Alzaid F, Blazek K, Eames HL, Lebozec K, Pini M, Hainault I, Montastier E, Denis RG, Ancel P, Lacombe A, Ling Y, Allatif O, Cruciani-Guglielmacci C, André S, Viguier N, Poitou C, Stich V, Torcivia A, Foulfelle F, Luquet S, Aron-Wisniewsky J, Langin D, Clément K, Udolova IA, Vercellef N. IRF5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. *Nat Med*. 2015;21:610–618. doi: 10.1038/nm.3829.
- Weiss M, Byrne AJ, Blazek K, Saliba DG, Pease JE, Perocheau D, Feldmann M, Udolova IA. IRF5 controls both acute and chronic inflammation. *Proc Natl Acad Sci U S A*. 2015;112:11001–11006. doi: 10.1073/pnas.1506254112.
- Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M. *In vivo* silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. *J Am Coll Cardiol*. 2014;63:1556–1566. doi: 10.1016/j.jacc.2013.11.023.
- Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Puri SG, Reikter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. *Circulation*. 2003;108:1772–1778. doi: 10.1161/01.CIR.0000087481.55887.C9.
- Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. *Circulation*. 2006;113:2744–2753. doi: 10.1161/CIRCULATIONAHA.105.590018.
- Seneviratne AN, Cole JE, Goddard ME, Park I, Mohri Z, Sansom S, Udolova I, Krams R, Monaco C. Low shear stress induces M1 macrophage polarization in murine thin-cap atherosclerotic plaques. *J Mol Cell Cardiol*. 2015;89(Pt B):168–172. doi: 10.1016/j.yjmcc.2015.10.034.
- Purtha WE, Swiecki M, Colonna M, Diamond MS, Bhattacharya D. Spontaneous mutation of the Dock2 gene in *Irfs*<sup>-/-</sup> mice complicates interpretation of type I interferon production and antibody responses. *Proc Natl Acad Sci U S A*. 2012;109:E898–E904. doi: 10.1073/pnas.1118155109.
- Saliba DG, Heger A, Eames HL, Oikonomopoulos S, Teixeira A, Blazek K, Androulidaki A, Wong D, Goh FG, Weiss M, Byrne A, Pasparakis M, Ragoussis J, Udolova IA. IRF5:RelA interaction targets inflammatory genes in macrophages. *Cell Rep*. 2014;8:1308–1317. doi: 10.1016/j.celrep.2014.07.034.
- Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, Tabas IA. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. *J Clin Invest*. 2009;119:886–898. doi: 10.1172/JCI37262.
- Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. *Circ Res*. 2010;106:383–390. doi: 10.1161/CIRCRESAHA.109.210781.
- Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol*. 2010;10:36–46. doi: 10.1038/nri2675.
- Bouhail MA, Derudas B, Rigamonti E, Diévalart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPAR-gamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. *Cell Metab*. 2007;6:137–143. doi: 10.1016/j.cmet.2007.06.010.
- Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. *PLoS One*. 2010;5:e8852. doi: 10.1371/journal.pone.0008852.
- Han S, Liang CP, DeVries-Seimon T, Ranalletta M, Welch CL, Collins-Fletcher K, Accili D, Tabas I, Tall AR. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. *Cell Metab*. 2006;3:257–266. doi: 10.1016/j.cmet.2006.02.008.
- Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. MerTK receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of *apoE*<sup>-/-</sup> mice. *Arterioscler Thromb Vasc Biol*. 2008;28:1421–1428. doi: 10.1161/ATVBAHA.108.167197.
- Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. *J Exp Med*. 2006;203:2073–2083. doi: 10.1084/jem.20060245.
- Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC, Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM. Functional role of CD11c+ mono-

- cytes in atherogenesis associated with hypercholesterolemia. *Circulation*. 2009;119:2708–2717. doi: 10.1161/CIRCULATIONAHA.108.823740.
27. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nat Rev Immunol*. 2011;11:750–761. doi: 10.1038/nri3088.
  28. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity*. 2014;41:14–20. doi: 10.1016/j.immuni.2014.06.008.
  29. Sándor N, Lukácsi S, Ungai-Salánki R, Orgován N, Szabó B, Horváth R, Erdei A, Bajtay Z. CD11c/CD18 dominates adhesion of human monocytes, macrophages and dendritic cells over CD11b/CD18. *PLoS One*. 2016;11:e0163120. doi: 10.1371/journal.pone.0163120.
  30. Netea MG, Demacker PN, Kullberg BJ, Boerman OC, Verschuuren I, Stalenhoef AF, Van Der Meer JW. Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. *Immunology*. 1998;95:466–472.
  31. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest*. 2007;117:175–184. doi: 10.1172/JCI29881.
  32. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ. Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 2007;27:621–627. doi: 10.1161/01.ATV.0000254673.55431.e6.
  33. Mälarstig A, Sigurdsson S, Eriksson P, Paulsson-Berne G, Hedin U, Wallentin L, Siegbahn A, Hamsten A, Syvänen AC. Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction. *Arterioscler Thromb Vasc Biol*. 2008;28:975–982. doi: 10.1161/ATVBAHA.108.163733.
  34. Feng X, Deng T, Zhang Y, Su S, Wei C, Han D. Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor  $\alpha$  and growth arrest-specific gene 6. *Immunology*. 2011;132:287–295. doi: 10.1111/j.1365-2567.2010.03364.x.
  35. McPhillips K, Janssen WJ, Ghosh M, Byrne A, Gardai S, Remigio L, Bratton DL, Kang JL, Henson P. TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic phospholipase A2 and oxidant-dependent mechanisms. *J Immunol*. 2007;178:8117–8126.
  36. Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, Vandivier RW, Harry BL, Riches DW, Henson PM, Bratton DL. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. *Blood*. 2009;113:2047–2055. doi: 10.1182/blood-2008-05-160564.
  37. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. *Nat Rev Immunol*. 2008;8:327–336. doi: 10.1038/nri2303.
  38. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. *Nature*. 2002;417:182–187. doi: 10.1038/417182a.
  39. Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, Blanc-Brude O, Barateau V, Potteaux S, Merval R, Esposito B, Teissier E, Daemen MJ, Lesèche G, Boulanger C, Tedgui A, Mallat Z. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. *Circulation*. 2007;115:2168–2177. doi: 10.1161/CIRCULATIONAHA.106.662080.
  40. Heng TS, Painter MW; Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. *Nat Immunol*. 2008;9:1091–1094. doi: 10.1038/ni1008-1091.

## Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis

Anusha N. Seneviratne, Andreas Edsfeldt, Jennifer E. Cole, Christina Kassiteridi, Maarten Swart, Inhye Park, Patricia Green, Tariq Khoyratty, David Saliba, Michael E. Goddard, Stephen N. Sansom, Isabel Goncalves, Rob Krams, Irina A. Udalova and Claudia Monaco

*Circulation*. 2017;136:1140-1154; originally published online July 11, 2017;  
doi: 10.1161/CIRCULATIONAHA.117.027844

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2017 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/content/136/12/1140>

Free via Open Access

Data Supplement (unedited) at:

<http://circ.ahajournals.org/content/suppl/2017/07/11/CIRCULATIONAHA.117.027844.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation* is online at:  
<http://circ.ahajournals.org/subscriptions/>



## SUPPLEMENTAL MATERIAL

### Expanded Materials and Methods

#### *Atherosclerosis time-course*

Mice were weaned at 4 weeks of age and fed a standard chow diet for the duration of the experiment. At 15, 20 or 27 weeks of age, ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice were euthanized with a barbiturate overdose and blood collected by cardiac puncture. Hearts were perfused *in situ* with saline via a cannula inserted into the left ventricle (outflow via an incision in the right atrium) and then the top halves of the heart were frozen in OCT embedding medium. The aorta and para-aortic lymph nodes were snap frozen for RNA extraction. Terminal blood was centrifuged at 6000rpm for 30 minutes at 4°C and serum collected. All tissues were stored at -80°C.

#### *Surgical placement of a perivascular flow-modifying cast*

Mice were placed on a cholate-free high fat diet (diet W) from Special Diets Services (Essex, UK) at 17-19 weeks of age. Two weeks later, mice were anaesthetised and a perivascular cast was tied around the right common carotid artery as previously described<sup>1</sup>. Nine weeks after cast placement, mice were euthanized and lesion development assessed as described.

#### *Aortic root atherosclerotic lesion measurement*

Five micrometer cryosections were taken of the aortic root for the entire region of the valve leaflets and every 20th section (100µm) was stained with Oil Red O and counterstained with hematoxylin. Aortic root sections were coded and analyzed blind. Images were captured under identical microscope, camera and light conditions using an Olympus BX51 osteometric brightfield & fluorescence microscope (Olympus). Quantification was performed by drawing around the atherosclerotic lesions and the aortic wall using Clemex Vision Lite version 5.0 (Clemex, Longueuil, Canada). Absolute values for cross-sectional area were obtained by calibrating the software using an image of a micrometer slide taken at the same magnification. The individual lesion areas per aortic root section were averaged to obtain the mean lesion area per mouse. The lesion area fraction was calculated by dividing the mean lesion area by the mean area of the aortic wall and expressed as a percentage.

#### *Measurement of lesion formation in perivascular cast-induced injury*

Nine weeks following cast placement, mice were euthanized, terminal blood collected via cardiac puncture and the vasculature perfused with 0.9% w/v saline. The injured carotid was dissected out and frozen at -80°C in Optimal cutting temperature (OCT) compound (ThermoScientific, Runcorn, UK). Serial 5µm cryosections were taken through the entire length of the carotid artery. Staining of the elastic lamina was performed using the Accustain kit (Sigma-Aldrich Inc., St. Louis, USA) according to the manufacturer's instructions. Measurement of lesion and vessel areas was performed using ProgRes CapturePro image analysis software (version 2.5.2.0, Jenoptik, Germany). The area between the internal and external elastic lamina was taken as the medial area and the intimal area was calculated by subtracting the lumen area from the internal elastic lamina area. The intimal medial ratio (IMR) was then calculated by dividing the intimal area by the medial area.

#### *Hematoxylin and Eosin (H+E) staining and necrosis quantification*

H+E staining was performed using a Tissue Tek Prisma/Film automated slide stainer (Sakura, Japan). Slides were fixed in 10% buffered formalin for 10 minutes, rinsed in distilled water and then stained with Harris hematoxylin for 8 minutes, washed in running tap water for 5 minutes, and differentiated with 0.3% acid alcohol for 2 minutes and rinsed in distilled water. The slides were counterstained with eosin for 2 minutes before being rinsed in distilled water. Necrotic areas (defined as being H+E free) were quantified using Clemex Vision Lite version 5.0. Only areas larger than 3000µm<sup>2</sup> in the aortic root and 300µm<sup>2</sup> in the carotid were included in the analysis. Absolute values were obtained by calibrating the software using an image of a micrometer slide taken at the same magnification. Necrotic lesion area was calculated by dividing the necrosis area by the lesion area and expressing it as a percentage.

#### *Murine Immunohistochemistry*

Immunohistochemistry was performed on 5µm cryosections using standard avidin biotinylated enzyme complex (ABC) methods as previously published<sup>2</sup>. In brief, sections were fixed in ice-cold acetone before incubation with 10% normal rabbit or goat serum for one hour. Following a wash in PBS, endogenous avidin and biotin were blocked using Vector avidin/biotin blocking kit (Vector labs, Peterborough, UK) according to manufacturer's instructions. Sections were then incubated with primary

antibodies against CD11c (BD Biosciences 2.5 $\mu$ g/mL), CD68 (AbD Serotec, 5 $\mu$ g/ml), iNOS (Abcam, 1 $\mu$ g/mL), CD206 (AbD Serotec, 5 $\mu$ g/mL), IRF5 (Abcam, 0.5 $\mu$ g/mL) or HO-1 (Abcam, 5 $\mu$ g/mL) for 45 minutes at room temperature, followed by relevant biotinylated secondary antibodies. Following blocking of endogenous peroxidase activity with 0.3% hydrogen peroxide, sections were incubated with avidin and biotinylated horseradish peroxidase macromolecular complexes using Vectastain Elite ABC kit (Vector Labs) according to manufacturer's instructions. Bound peroxidase was detected using 3,3'-diaminobenzidine (DAB) and nuclei counterstained with hematoxylin. Staining using an appropriate isotype-matched control was performed on a consecutive section as a control. Smooth muscle cell staining was performed using an antibody against alpha smooth muscle actin conjugated to Cy3 (Sigma 5 $\mu$ g/mL) and DAPI counterstaining of nuclei.

#### *Immunofluorescence staining*

Dual staining of aortic root sections with antibodies against IRF5 and CD68, CD11c or  $\alpha$ -smooth muscle actin was performed using tyramide signal amplification (TSA) using a biotin-TSA kit as per manufacturer's instructions (Perkin Elmer). In brief, 5 $\mu$ m cryosections were fixed in ice-cold acetone for 5 minutes before endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in PBS for 15 minutes. Endogenous avidin and biotin activity were then blocked using the Vector avidin/biotin blocking kit. Following blocking with 20% normal goat serum for one hour, sections were blocked with TNB blocking buffer (0.1M Tris-HCl pH 7.5, 0.15M NaCl, 0.5% blocking buffer as supplied in kit) for 30 minutes before incubation with an antibody against IRF5 (Abcam, 0.5 $\mu$ g/mL) for 45 minutes. Following washing, sections were incubated with relevant biotinylated secondary antibodies then incubated with streptavidin-HRP for 30 minutes. Biotinyl tyramide working solution was then added for 5 minutes followed by streptavidin-Alexa Fluor 488 (Life Technologies). Sections were then re-blocked and stained with an antibody against CD68 (AbD Serotec, 5 $\mu$ g/mL) or CD11c (AbD Serotec 20 $\mu$ g/mL) and an Alexa Fluor 568 conjugated secondary antibody and DAPI (Life technologies). Alternatively, slides were stained with an antibody against alpha smooth muscle actin conjugated to Cy3 (Sigma 5 $\mu$ g/mL) and DAPI. Slides were viewed on an Ultraview confocal microscope (PerkinElmer Life Sciences, Cambridge, UK).

#### *Quantification of murine immunohistochemical staining*

For all quantification, images were captured under identical microscope, camera and light conditions, coded and analyzed blind. Aortic root lesion area staining positive for a given marker was quantified using Clemex Vision Lite version 5.0. Using the image analysis software, positive staining was detected and lesion area measured. Absolute values were obtained by calibrating the software using an image of a micrometer slide taken at the same magnification. Lesion area fraction staining positive was calculated by dividing the area staining positive by the lesion area and expressing it as a percentage.

#### *Analysis of serum cholesterol*

Total serum cholesterol levels were measured enzymatically using Infinity Total Cholesterol (Thermo Scientific), according to the manufacturer's instructions. A calibration serum (Randox Laboratories) with a known cholesterol concentration was used as a reference.

#### *In vitro bone marrow cell culture*

For *in vitro* experiments, bone marrow cells were isolated from tibia and femurs of 16-21 week old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Ir5<sup>-/-</sup> mice. The cells were cultured for 7 days in Roswell Park Memorial Institute (RPMI) 1640 medium containing 25 mM hepes (Lonza) supplemented with 10% fetal bovine serum (FBS; Labtech), 2.5µg/mL Amphotericin-B, 100U/mL penicillin, 100µg/mL streptomycin and 50µM 2-mercaptoethanol (all Gibco). The cells were cultured in the presence of 20ng/mL GM-CSF (PeproTech). In some experiments, GM-CSF-derived bone marrow cells underwent magnetic cell separation with CD11c MicroBeads (Miltenyi Biotec) and CD11c<sup>+</sup> and CD11c<sup>-</sup> bone marrow derived cells were cultured separately. Cells were either left unstimulated or stimulated with 100 ng/mL E. Coli derived LPS (Enzo Life Sciences, serotype: EH100 Ra) for 24 hours.

#### *In situ efferocytosis assay*

Sections of cast-induced carotid lesions were stained for apoptosis and DNA using the BrdU-Red DNA Fragmentation kit (TUNEL, ab66110 Abcam, Cambridge, UK) according to manufacturer's instructions. Slides were counterstained for macrophages using an antibody against CD68 (Alexa Fluor 647, AbD Serotec). The most stenotic part of each section was imaged using an Olympus FV1200 IX83



confocal system. Images were analyzed using ImageJ (1.50I, NIH, USA) and Photoshop CS6 (13.0.1x32, Adobe Systems Inc, USA). TUNEL+ apoptotic cells surrounded by a CD68+ cell were counted as cells undergoing efferocytosis, as previously described<sup>3</sup>. TUNEL+ apoptotic cells not surrounded by a CD68+ cell were counted as apoptotic cells not undergoing efferocytosis. All analysis was performed by 2 independent assessors blinded to the experiment details.

#### *Apoptosis, foam cell, efferocytosis and phagocytosis assays*

Foam cell assays were performed by incubating cultured cells with DiO-Ac-LDL (Bioquote). Apoptosis assays were performed by exposing cultured cells to UV light, then staining them for Annexin V-FITC and PI (Life Technologies). Phagocytosis assays were performed by incubating cultured cells with Fluoresbrite Yellow-Green microspheres (Polysciences Inc.). Efferocytosis assays were performed by incubating cultured cells with Calcein AM-labelled apoptotic Jurkat cells<sup>4</sup>.

#### *Transfection of murine GMCSF Macrophages with RNAi Oligos*

Bone marrow macrophages were generated as above and were then plated at  $1 \times 10^6$  in a 12 well plate with 20ng/ml fresh GMCSF overnight at 37°C. The next day, the oligo (ON-TARGET plus SMART pool siRNA for mouse Mfge8, Itgb3 or a non-targeting control, Dharmacon), Dharmafect 1 (Dharmacon) and Opti-mem (Gibco) mix was prepared to give a final concentration of 100nM of oligo and left to incubate 20min at RT. The macrophage growth media was then replaced with the relevant oligo-mix (in serum-free RPMI) and incubated at 37°C for 2hrs. After removal of the transfection complexes, 1ml of RPMI with 5%FCS was added to the well and the plate incubated for 48hrs at 37°C. The efferocytosis assay was then performed as described.

#### *Measurement of Mfge8 release*

Supernatants from GMCSF-derived bone marrow cultures were removed after one week and stored at -80°C for batch analysis. A commercially available mouse MFGE8 ELISA kit was used (Biolegend) in accordance with the manufacturer's instructions. Samples were run in duplicate.

### *Flow cytometric analysis*

Aortas and PALNs were harvested from 20 week old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice. Aortas, including the aortic arch, thoracic and abdominal portions were incubated with an enzyme cocktail containing 230U/ml collagenase I, 144U/ml collagenase XI, 64U/ml hyaluronidase, 61U/ml DNase, 2mM CaCl<sub>2</sub> and 1mg/ml soybean trypsin inhibitor (Sigma-Aldrich) in PBS 1% FCS for 1 hour at 37°C. Post-digestion, single cell suspensions were obtained by mashing aortas through a 70µm cell strainer. Enzymatic digestion was not required for the PALN. For macrophage cell cultures, both adherent and non-adherent GMCSF matured macrophages were collected. All cell types were then incubated with 0.5mg/ml of Mouse Fc block (BD Biosciences) for 10 min at 4°C before incubation with antibodies.

Antibodies against the following antigens were used: MHCII (clone M5/114, BD Pharmingen), F4/80 (clone BM8, Biolegend), CD11c (clone N418, Biolegend), CD11b (clone M1/70 Biolegend), CD103 (clone 2E7, Biolegend), MerTK (clone 108928, R&D systems), Itgb3 (clone 2C9.G2, BD Biosciences) and CD45 (clone 30-F11, Biolegend). Cells were additionally stained with the Live/Dead Fixable Dead Cell Stain kit according to the manufacturer's instructions (Life technologies). Cells were washed and then fixed with BD CellFIX (BD Biosciences). All gates were based on fluorescence minus one (FMO) controls. Fluorescent labels were detected with a BD LSRII flow cytometer (BD Biosciences) and results were analyzed using FlowJo software 10.07 (FlowJo, USA). The main myeloid cell populations were gated as previously described by Helft *et al*<sup>5</sup>.

### *Real time quantitative PCR*

Total RNA was extracted from GMCSF matured macrophages, aorta and PALN from 20 week old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice using a Qiagen RNeasy mini kit, according to manufacturer's instructions. Total RNA was reverse transcribed to cDNA using a High Capacity Reverse Transcription Kit (Life Technologies). Following preamplification (14 cycles), RT-PCR was performed using either custom TaqMan Array microfluidic cards or individual TaqMan Gene Expression Assays and TaqMan universal PCR Master Mix (Life technologies) on an ABI 7900HT fast real-time PCR system (Applied Biosystems). PCR amplification was carried out for 40 cycles. All samples were analysed in triplicate and were normalized to 18s. The 2-ΔΔCt method was used to analyse the relative changes in gene expression.

### *Chromatin immunoprecipitation and next-generation sequencing*

The IRF5 ChIP-seq analysis were performed as previously described (Accession number: E-MTAB-2661)<sup>6</sup>. 300 million GMCSF matured bone marrow derived macrophages from wild type and *Irf5*<sup>-/-</sup> mice were used for IRF5 ChIP following stimulation with LPS for 0 and 2hrs in duplicate. Cells were fixed for 10 minutes with 1% formaldehyde, quenched with 125mM of Tris pH7.5 and washed with ice-cold PBS. Nuclear lysates were isolated as previously described and sonicated with a Bioruptor (Diagenode) to obtain chromatin fragment sizes that average 300bp. Each lysate was immunoprecipitated with 10µg of IRF5 antibody (Abcam; ab21689). ChIP was performed as described previously. ChIPped DNA was quantified with the Quant-iT dsDNA High Sensitivity Assay Kit (Invitrogen #Q33120). DNA yields ranged from 10–20 ng. The ChIP-Seq datasets were generated using 50bp paired end sequencing. Reads were trimmed using Trimmomatic, and mapped to the mm10 genome using Bowtie2. Before peak calling with MACS2 using the following settings: --mfold 10 30 --gsize mm --qvalue 0.05. Called peaks in the WT samples were then filtered against those in *Irf5*<sup>-/-</sup> to exclude any false positives. Read coverage profiles were computed with 25bp resolution and normalized by reads per kilobase per million mapped reads (RPKM) using deepTools. Called peaks and read coverage profiles were visualized using IGV.

### *Human carotid plaque sample preparation and histology*

Human carotid plaques from the Carotid Plaque Imaging Project (CPIP) biobank (Malmö, Sweden) were analyzed. Plaques were collected at carotid endarterectomy and the indications for surgery were plaques associated with ipsilateral symptoms (Transitory ischemic attack, stroke or amaurosis fugax) and >70% stenosis, measured by duplex, or plaques not associated with symptoms and stenosis >80%.

After surgical removal, plaques were snap-frozen in liquid nitrogen. Fragments (1mm) from the most stenotic region of the plaque were used for histology. Sections were stained with antibodies against CD68 (Dako cytomatic, 1.85µg/mL), alpha-smooth muscle actin (Dako cytomatic, 0.71µg/mL), IRF5 (Abcam, 20µg/mL) or CD11c (Abcam, 1µg/mL) or relevant isotype control antibodies. Following incubation with an appropriate secondary antibody or MACH3 mouse polymerase kit (Biocare Medical), 3,3'- diaminobenzidine (DAB) was used for staining detection and nuclei were counterstained with Mayer's hematoxylin. Quantification of the area of plaque

staining positive (% area) for the different stains was performed blind using BiopixiQ 2.1.8 (Gothenburg, Sweden) after imaging with ScanScope Console Version 8.2 (LRI imaging AB, Vista CA, USA).

## Supplemental Tables

**Supplemental Table 1: Summary of results of robust 2-way ANOVA analysis of the data shown in Figure 1**

Variable	Factor	p-value Area (%)	p-value Area (absolute)
<i>Lesion area</i>	Genotype	0.029	0.129
	Time (weeks)	0.001	0.001
	Genotype:Time	0.749	0.273
<i>Necrotic core</i>	Genotype	0.001	0.001
	Time (weeks)	0.001	0.001
	Genotype:Time	0.001	0.001

**Supplemental Table 2: Summary of results of robust 2-way ANOVA analysis of the data shown in Figure 2**

Variable	Factor	p-value Area (%)	p-value Area (absolute)
<i>CD68</i>	Genotype	0.045	0.278
	Time (weeks)	0.120	0.001
	Genotype:Time	0.860	0.750
<i>CD11c</i>	Genotype	0.001	0.001
	Time (weeks)	0.216	0.003
	Genotype:Time	0.015	0.013
<i>CD206</i>	Genotype	0.007	0.009
	Time (weeks)	0.051	0.001
	Genotype:Time	0.435	0.174

**Supplemental Table 3: Summary of results of robust mixed 2-way ANOVA analysis of the data shown in Figure 4**

Variable	Factor	p-value Area (%)	p-value Area (absolute)
<i>Necrotic core</i>	Genotype	0.00496	0.01165
	Stress	0.02844	0.03309
	Genotype:Stress	0.00153	0.00263
<i>CD68</i>	Genotype	0.757	0.982
	Stress	0.122	0.394
	Genotype:Stress	0.774	0.207
<i>CD11c</i>	Genotype	0.00427	0.0264
	Stress	0.17554	0.0962
	Genotype:Stress	0.17594	0.0934
<i>Asma</i>	Genotype	0.0348	0.068
	Stress	0.0134	6.66e-06
	Genotype:Stress	0.1129	2.36e-03



**Supplemental Table 4: Summary of results of robust 2-way ANOVA analysis of the data shown in Supplemental Figure 2**

Variable	Factor	p-value Area (%)	p-value Area (absolute)
<i>Asma</i>	Genotype	0.129	0.938
	Time (weeks)	0.047	0.003
	Genotype:Time	0.116	0.983
<i>HO-1</i>	Genotype	0.001	0.336
	Time (weeks)	0.817	0.001
	Genotype:Time	0.003	0.221
<i>iNOS</i>	Genotype	0.284	0.315
	Time (weeks)	0.001	0.001
	Genotype:Time	0.365	0.315

**Supplemental Table 5: Summary of results of robust mixed 2-way ANOVA analysis of the data shown in Supplemental Figure 3**

Variable	Factor	p-value
<i>IMR</i>	Genotype	0.485
	Stress	0.140
	Genotype:Stress	0.298

**Supplemental Table 6. Final body weight and serum cholesterol levels in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>lrf5<sup>-/-</sup> mice**

Mouse genotype	Age (wk)	Final body weight ± SEM (g)	p-value vs. ApoE <sup>-/-</sup>	Serum cholesterol ± SEM (mg/dL)	p-value vs. ApoE <sup>-/-</sup>
ApoE <sup>-/-</sup>	15	30.2 ± 0.8	-	286.2 ± 30.9	-
ApoE <sup>-/-</sup> lrf5 <sup>-/-</sup>	15	32.5 ± 0.5	<b>0.019</b>	301.6 ± 15.5	0.620
ApoE <sup>-/-</sup>	20	32.1 ± 0.5	-	382.8 ± 58	-
ApoE <sup>-/-</sup> lrf5 <sup>-/-</sup>	20	32.1 ± 0.5	0.991	510.4 ± 81.2	0.213
ApoE <sup>-/-</sup>	27	32.9 ± 0.6	-	471.8 ± 88.9	-
ApoE <sup>-/-</sup> lrf5 <sup>-/-</sup>	27	33.6 ± 0.6	0.417	467.9 ± 69.6	0.954

**Supplemental Table 7. Body weight and final serum cholesterol levels in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>lrf5<sup>-/-</sup> mice that underwent cast-placement surgery**

Mouse genotype	Age (wk)	Final body weight ± SEM (g)	p-value vs. ApoE <sup>-/-</sup>	Serum cholesterol ± SEM (mg/dL)	p-value vs. ApoE <sup>-/-</sup>
ApoE <sup>-/-</sup>	15-17	31.0 ± 0.4	-	-	-
ApoE <sup>-/-</sup> lrf5 <sup>-/-</sup>	15-17	34.1 ± 0.5	<b>&lt;0.0001</b>	-	-
ApoE <sup>-/-</sup>	24-26	32.7 ± 0.7	-	564.6 ± 77.3	-
ApoE <sup>-/-</sup> lrf5 <sup>-/-</sup>	24-26	40.4 ± 1.7	<b>0.0008</b>	618.7 ± 58	0.5914

**Supplemental Table 8. iNOS, CD206 and HO-1 expression in perivascular shear stress altering cast-induced lesions in ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice**

Mouse Genotype	Flow region	iNOS expression ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>	CD206 expression ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>	HO-1 expression ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>
ApoE <sup>-/-</sup>	Low	15.7±2.7	-	4.0±0.9	-	8.8±4.4	-
ApoE <sup>-/-</sup> Irf5 <sup>-/-</sup>	Low	13.6±5.0	0.76	6.3±3.1	0.73	3.0±1.8	0.26
ApoE <sup>-/-</sup>	Oscillatory	14.5±3.1	-	10.2±1.2	-	11.3±5.2	-
ApoE <sup>-/-</sup> Irf5 <sup>-/-</sup>	Oscillatory	9.7±3.4	0.35	11.0±2.8	0.91	11.4±2.8	0.61

**Supplemental Table 9. Percentage of foam cells in bone marrow derived cultures of ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice**

Sorted population	Treatment	ApoE <sup>-/-</sup> Mean ± SEM (%)	ApoE <sup>-/-</sup> Irf5 <sup>-/-</sup> Mean ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>
CD11c+	None	31.1 ± 7.5	30.6 ± 7.3	0.965
	LPS	29.1 ± 10.5	30.2 ± 7.3	0.939
CD11c-	None	27.2 ± 1.7	28.0 ± 1.8	0.768
	LPS	24.1 ± 4.5	25.3 ± 4.1	0.854

**Supplemental Table 10. Percentage of phagocytosis in bone marrow-derived cultures of ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice**


Sorted population	Treatment	ApoE <sup>-/-</sup> Mean ± SEM (%)	ApoE <sup>-/-</sup> Irf5 <sup>-/-</sup> Mean ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>
CD11c+	None	33.9 ± 5.8	27.9 ± 2.4	0.374
	LPS	36.5 ± 5.7	30.6 ± 3.0	0.394
CD11c-	None	27.7 ± 3.0	32.7 ± 4.4	0.380
	LPS	33.1 ± 5.2	32.4 ± 3.5	0.915

**Supplemental Table 11. Percentage of apoptotic cells in bone marrow GMCSF-derived cultures of ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup>Irf5<sup>-/-</sup> mice**

Sorted population	Treatment	Cell population	ApoE <sup>-/-</sup> Mean ± SEM (%)	ApoE <sup>-/-</sup> Irf5 <sup>-/-</sup> Mean ± SEM (%)	p-value vs. ApoE <sup>-/-</sup>
CD11c+	None	Live	20.5 ± 10.6	20.1 ± 10.6	0.984
		Annexin +	59.2 ± 17.1	67.0 ± 13.7	0.734
		Annexin+ PI+	10.4 ± 1.6	6.9 ± 1.9	0.211
	LPS	Live	23.5 ± 11.6	20.6 ± 9.7	0.856
		Annexin +	49.6 ± 14.3	65.1 ± 14.1	0.471
		Annexin+ PI+	11.2 ± 5.7	7.8 ± 1.8	0.169
CD11c-	None	Live	27.8 ± 12.4	21.6 ± 9.8	0.709
		Annexin +	59.9 ± 11.9	65.3 ± 14.7	0.784
		Annexin+ PI+	8.9 ± 6.1	6.1 ± 1.9	0.410
	LPS	Live	27.5 ± 12.3	24.9 ± 10.6	0.879
		Annexin +	56.5 ± 16.2	66.1 ± 13.0	0.660
		Annexin+PI+	14.9 ± 3.6	3.1 ± 0.8	<b>0.00005</b>

## Supplemental Figures


### Supplemental Figure 1



### Supplemental Figure 1. IRF5 expression in aortic root lesions of ApoE<sup>-/-</sup> mice.

**A)** Representative images of aortic root sections from ApoE<sup>-/-</sup> mice aged 12, 20 and 27 weeks stained with an antibody against IRF5 or CD68 (brown staining) and hematoxylin. Scale bar = 100μm. Graphs show aortic root lesion area staining positive (x10<sup>3</sup> μm<sup>2</sup> and %) for CD68 and IRF5 in 12 to 27 week old ApoE<sup>-/-</sup> mice. Bars show mean + SEM. n=3-4 \*p<0.05, \*\*\*p<0.001 **B-D)** Dual immunofluorescent staining and confocal analysis of IRF5 and CD68 (**B**), CD11c (**C**) or αSM actin (**D**) expression in aortic root sections of 30 week old ApoE<sup>-/-</sup> mice fed a chow diet. Aortic root sections were dual immunostained with an antibody against IRF5 (Alexa 488, green emission), with tyramide signal amplification, and with either an antibody against the pan-macrophage marker CD68 (Alexa 568, red emission), an antibody against CD11c (Alexa 568, red emission) or an antibody against αSM actin (Cy3, red emission). Sections were counterstained with DAPI. Composite pseudocolour images; Green, Irf5; Red, CD68, CD11c or αSM actin and Blue, DAPI nuclear dye. Dotted line denotes internal elastic lamina. Zoom image of area denoted by white box in composite pseudocolour image.


## Supplemental Figure 2



**Supplemental Figure 2. Immunohistochemistry in aortic root lesions of  $ApoE^{-/-}$  versus  $ApoE^{-/-}Irf5^{-/-}$  mice.** **A)** Representative photomicrographs of aortic root sections from 15, 20 and 27 week old  $ApoE^{-/-}$  and  $ApoE^{-/-}Irf5^{-/-}$  mice stained with an antibody against smooth muscle cell  $\alpha$ -actin (ASMA) (Cy3-red) and DAPI (blue). L = lumen. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu m^2$  and %) for ASMA. Scale bars = 100 $\mu m$ . **B)** Representative photomicrographs of aortic root sections from 15, 20 and 27 week old  $ApoE^{-/-}$  and  $ApoE^{-/-}Irf5^{-/-}$  mice stained with an antibody against HO-1 (brown staining) and hematoxylin. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu m^2$  and %) for HO-1. **C)** Representative photomicrographs of aortic root sections from 15, 20 and 27 week old  $ApoE^{-/-}$  and  $ApoE^{-/-}Irf5^{-/-}$  mice stained with an antibody against iNOS (brown staining) and hematoxylin. Graphs show aortic root lesion area staining positive ( $\times 10^3 \mu m^2$  and %) for iNOS. Arrows highlight positive cells. Each circle represents the mean positive area per individual mouse. Horizontal line denotes group mean. \*\* $p<0.01$ ,  $n=9-10$ .




### Supplemental Figure 3



**Supplemental Figure 3. Lesion size in a murine model of TCFA.** *ApoE*<sup>-/-</sup> (black circles) and *ApoE*<sup>-/-</sup> *Irf5*<sup>-/-</sup> mice (white circles) were placed on high fat diet at 17-18 weeks of age. After 2 weeks, a perivascular shear stress altering cast was surgically placed around the common carotid artery and left in place for 9 weeks. Representative images of carotid artery sections stained with Elastin-Van Gieson stain, Scale bars = 100 μm. Each circle represents the mean Intima:Media ratio (IMR) of carotid artery regions 9 weeks after cast placement per individual mouse. Horizontal line denotes group median. \*p<0.05 n=8


## Supplemental Figure 4

**A**




**B**

Gated on live CD45+ F4/80+ cells




**C**

Gated on live CD45+ F4/80+MerTK+ cells




**D**

Gated on live CD45+F4/80- cells




**Supplemental Figure 4. Representative staining and gating of aortic myeloid cell subsets.** Aortas were harvested and enzymatically digested then stained with antibodies against myeloid cell markers and a live/dead stain. **A)** Representative plots showing cell gating. To gate myeloid cells, doublets were excluded before CD45+ were gated. Live CD45+ cells were then gated. **B)** Representative plot showing macrophage CD11b+CD11c+ gate (cells gated as CD45+F4/80+) **C)** Representative plot showing macrophage CD11b+CD11c+ gate (cells gated as CD45+F4/80+MerTK+) **D)** Representative plots showing dendritic cell gating. CD45+F4/80- cells were further gated as CD11c+MHCII+ and these cells were then separated on the basis of CD11b and CD103 expression.

# Supplemental Figure 5




**Supplemental Figure 5. Representative staining and gating of bone marrow GM-CSF cultured myeloid cell subsets.** Cells were gated as MHCII<sup>int-high</sup> and CD11c<sup>+</sup> or MHCII<sup>low</sup>CD11c<sup>-</sup>. CD11c<sup>+</sup>MHCII<sup>int-high</sup> cells were then further gated as CD11b<sup>high</sup>MHCII<sup>int</sup> to identify macrophages and CD11b<sup>int</sup>MHCII<sup>high</sup> to identify dendritic cells. For CD11c<sup>-</sup> cells, cells were further gated as CD11b<sup>low-high</sup> and MHCII<sup>low/int</sup>.

**Supplemental Figure 6**



**Supplemental Figure 6. CD11b+ dendritic cells are decreased in the aorta of IRF5 deficient mice.** Aortas were harvested from 21-24 week old ApoE<sup>-/-</sup> and ApoE<sup>-/-</sup> Irf5<sup>-/-</sup> mice. Single cell suspensions were then stained with antibodies against myeloid cell markers and analysed by flow cytometry. Dead cells and debris were excluded from the analysis and cells were gated on CD45+ cells. Graphs show the numbers of aortic CD45+F4/80-CD11c+MHCII+ cells that were CD11b+CD103- (left graph) or CD11b-CD103+ (right graph). Each circle represents an individual mouse. Horizontal line denotes group mean. \*p<0.05 n=8.


## Supplemental Figure 7



**Supplemental Figure 7. IRF5 is expressed by CD11c+ cells in human carotid plaques.** **A)** Representative images of a human carotid plaque stained with antibodies against CD68, CD11c, IRF5 and  $\alpha$ SM actin (brown staining) and hematoxylin. Dashed line denotes necrotic core. Far left image: x2 magnification, scale bar = 1mm. Other images represent x10 magnification of area of plaque denoted by box in x2 magnification image, scale bar = 200 $\mu$ m. **B)** Scatter plot graph showing the Spearman correlation between IRF5 and CD11c positively stained areas in the human carotid plaques. Each dot represents an individual human carotid plaque  $r=0.57$ ,  $p<0.05$ ;  $n=17$ .



**Supplemental Figure 8**



**Supplemental Figure 8. IRF5 controls the formation of the necrotic core impairing efferocytosis.** The diagram summarizes the findings of our study. IRF5 drives the expression of CD11c on activated macrophages with pro-inflammatory properties. Its deletion in atherosclerosis causes a switch from CD11c expressing to ITGβ3 expressing macrophages enhancing efferocytosis and preventing the formation of the necrotic core.

## Supplemental References

1. Cheng C, Tempel D, van Haperen R, van Der Baan A, Grosveld F, Daemen MJAP, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. *Circulation*. 2006;113:2744-2753. doi:10.1161/CIRCULATIONAHA.105.590018
2. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C. Unexpected protective role for Toll-like receptor 3 in the arterial wall. *Proc Natl Acad Sci U S A*. 2011;108:2372-2377. doi:10.1073/pnas.1018515108
3. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. MERTK receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe<sup>-/-</sup> mice. *Arterioscler Thromb Vasc Biol*. 2008;28:1421-1428. doi:10.1161/ATVBAHA.108.167197
4. Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, Tabas IA. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. *J Clin Invest* 2009;119:886-898. doi:10.1172/JCI37262
5. Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Schraml BU, Goubau D, Reis e Sousa C. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. *Immunity*. 2015;42:1197-1211. doi:10.1016/j.immuni.2015.05.018
6. Saliba DG, Heger A, Eames HL, Oikonomopoulos S, Teixeira A, Blazek K, Androulidaki A, Wong D, Goh FG, Weiss M, Byrne A, Pasparakis M, Ragoussis J, Udalova IA. IRF5:RelA interaction targets inflammatory genes in macrophages. *Cell Rep*. 2014;8:1308-1317. doi:10.1016/j.celrep.2014.07.034